According to Sandoz, Ireland and the Czech Republic have approved marketing applications for the AirFluSal Forspiro salmeterol/fluticasone DPI in 50-250 and 50-500 µg dosage forms for the treatment of asthma and/or COPD. The Czech approval triggers a €1.5 million milestone payment from Sandoz to Vectura. Sandoz Head of Global Respiratory Jan-Torsten Tews said, “We … [Read more...] about Two more approvals for AirFluSal Forspiro
News
GSK Australia to add Ventolin nebules production capacity
GSK Australia has announced that it plans to invest AUD31 million in blow-fill-seal equipment for the manufacture of Venolin salbutamol nebules at its facility in Boronia, a suburb of Melbourne. The company cited increasing demand for asthma treatments from Turkey, Brazil, and China as the reason for the retrofit. The Boronia site is GSK's largest liquid product … [Read more...] about GSK Australia to add Ventolin nebules production capacity
Catalent acquires Micron Technologies
CDMO Catalent has announced its acquisition of particle size reduction specialist Micron Technologies, which offers micronization, milling, and particle characterization services for pharmaceutical products, including inhalation powders. Catalent notes that it offers development through to commercial manufacturing for inhaled products, including potent compounds. … [Read more...] about Catalent acquires Micron Technologies
Company files patent applications for novel intranasal delivery system
US-based AirWare Labs says that it has filed patent applications for an intranasal drug delivery system that will include "AirWare Labs' patent-pending disposable sealed cartridge and patent-pending nasal insert system with insufflation plugins, both of which can be filled with medication in powder form." The company currently markets a line of disposable nasal … [Read more...] about Company files patent applications for novel intranasal delivery system
Aegis Therapeutics gets patent for intranasal CNS drug delivery
The US Patent and Trademark Office (USPTO) has awarded US Patent No 8,883,728, "Intranasal administration of active agents to the central nervous system," to Aegis Therapeutics, the company said. The patent covers, "Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are … [Read more...] about Aegis Therapeutics gets patent for intranasal CNS drug delivery
LSTM gets grant to study nasal spray flu vaccine versus pneumococcal bacteria
The Bill and Melinda Gates Foundation has awarded a $2.5 million grant to researchers at Liverpool School of Tropical Medicine (LSTM) for a study to determine the effects of nasal spray flu vaccine on pneumococcal bacteria. The 2-year study, to be conducted in conjunction with the Royal Liverpool University Hospital, will recruit almost 300 volunteers, half of … [Read more...] about LSTM gets grant to study nasal spray flu vaccine versus pneumococcal bacteria
Avanir says NDA for AVP-825 unlikely to be approved by PDUFA date
According to Avanir Pharmaceuticals,the FDA has issued a Discipline Review letter in response to the company's NDA for AVP-825 intranasal dry powder sumatriptan requesting that the company "optimize the product-user interface" and conduct additional human factor testing. AVP-825 is delivered using OptiNose's Breath Powdered intranasal delivery device. Although the … [Read more...] about Avanir says NDA for AVP-825 unlikely to be approved by PDUFA date
RespiTech team gets grant for development of inhalable Smartdrops technology
The Australian Research Council has awarded a $521,800 grant to Daniela Traini and Paul Young of the Woolcock Institute's RespiTech group and Patrick Spicer of the University of New South Wales for development of inhalable "Smartdrops" for drug delivery to the lung. The three-year project is designed to develop a microfluidics-based process for creating … [Read more...] about RespiTech team gets grant for development of inhalable Smartdrops technology
Over 700 employees transfered from Almirall to AstraZeneca as part of respiratory drug deal
As AstraZeneca completes the acquisition of Almirall's respiratory drug franchise, which was first announced in July 2014, Almirall says that 719 employees will transfer to AstraZeneca. The deal includes the inhalation R&D company Almirall Sofotec as well as a number of inhalers, including the Eklira/Bretaris/Tudorza aclidinium DPI, the Duaklir Genuair … [Read more...] about Over 700 employees transfered from Almirall to AstraZeneca as part of respiratory drug deal
Sales of Zomig nasal spray increase 54%
Impax Laboratories has reported a 19.1% increase in total revenues for the quarter ended September 30, 2014 compared to the third quarter of the prior year. The company attributes a portion of the increase in revenues to a 54% increase in sales of Zomig zolmitriptan nasal spray, which it markets in the US for the treatment of migraine. Impax acquired the rights to … [Read more...] about Sales of Zomig nasal spray increase 54%